697. 8 Years of Characteristics and Outcomes of Patients with MRSA Endocarditis Based on Vancomycin Minimum Inhibitory Concentration: Experience at a Tertiary Care Hospital

BACKGROUND: Vancomycin has been the mainstay of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infective endocarditis (IE). MRSA reduced susceptibility to vancomycin is a growing threat. Data assessing the effect of vancomycin reduced susceptibility on outcomes is limited. Our stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Alpizar-Rivas, Rodolfo M, Balda, Javier, Elarabi, Salwa, Jaber, Bertrand, Nader, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777712/
http://dx.doi.org/10.1093/ofid/ofaa439.889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777712/
http://dx.doi.org/10.1093/ofid/ofaa439.889

Ejemplares similares